Trial · NCT03123276
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Dose Limiting Toxicities. | Cohort 1 - 800mg/m2 Gemcitabine | 0 | Participants | ||
| Number of Patients With Dose Limiting Toxicities. | Cohort 2 - 1000mg/m2 of Gemcitabine | 1 | Participants | ||
| Number of Patients With Dose Limiting Toxicities. | Cohort 3 - 1200mg/m2 Gemcitabine | 0 | Participants | ||
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Cohort 1: 800mg/m2 Gemcitabine | Objective response rate (ORR) | 0 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Cohort 2: 1000mg/m2 Gemcitabine | Objective response rate (ORR) | 1 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Cohort 3: 1200mg/m2 Gemcitabine | Objective response rate (ORR) | 2 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Part B Dose Expansion Cohort - 1200mg/m2 Gemcitabine | Objective response rate (ORR) | 2 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Cohort 1: 800mg/m2 Gemcitabine | Disease control rate (DCR) | 3 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Cohort 2: 1000mg/m2 Gemcitabine | Disease control rate (DCR) | 6 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Cohort 3: 1200mg/m2 Gemcitabine | Disease control rate (DCR) | 1 | Participants | |
| Preliminary Evaluation of Response by Using RECIST v1.1. Number of Patients With Objective Response and Disease Control | Part B Dose Expansion Cohort - 1200mg/m2 Gemcitabine | Disease control rate (DCR) | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03123276/results